Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-C344749-100 100 Tests (1 mg/ml) $498 
LAG3 Antibody - Detection of endogenous human LAG-3 by FACS analysis using anti-LAG-3 (human), mAb (17B4) (ATTO 647) . Human PBMC were stimulated (B) or not (A) with 1 ug/ml of superantigen SEB. After 2 days PBMC were stained with 10 ug/ml (1 ug/0.5x106 cells) of anti-LAG-3 (human), mAb (17B4) (ATTO 647) and analyzed by flow cytometry. This image was taken for the unconjugated form of this product. Other forms have not been tested.

Monoclonal Mouse anti‑Human LAG3 Antibody (clone 17B4, Atto 647N, aa70‑99, IHC, WB) LS‑C344749

Monoclonal Mouse anti‑Human LAG3 Antibody (clone 17B4, Atto 647N, aa70‑99, IHC, WB) LS‑C344749

Antibody:
LAG3 Mouse anti-Human Monoclonal (aa70-99) (Atto 647N) (17B4) Antibody
Application:
IHC, IHC-Fr, ICC, WB, IP, Flo, Func
Reactivity:
Human
Format:
Atto 647N, Unmodified
Price
Catalog Number
$498
LS-C344749-100
Toll Free North America
206-374-1102
For Research Use Only

Overview

Antibody:
LAG3 Mouse anti-Human Monoclonal (aa70-99) (Atto 647N) (17B4) Antibody
Application:
IHC, IHC-Fr, ICC, WB, IP, Flo, Func
Reactivity:
Human
Format:
Atto 647N, Unmodified

Specifications

Description
LAG3 antibody LS-C344749 is an Atto 647N-conjugated mouse monoclonal antibody to human LAG3 (aa70-99). Validated for Flow, Func, ICC, IHC, IP and WB.
Target
Human LAG3
Synonyms
LAG3 | CD223 antigen | LAG-3 | Protein FDC | CD223 | FDC | Lymphocyte-activation gene 3
Host
Mouse
Reactivity
Human (tested or 100% immunogen sequence identity)
Clonality
IgG1 Monoclonal
Clone
17B4
Conjugations
Atto 647N. Also available Unconjugated or conjugated with Biotin, FITC, Atto 488, Atto 590.
Purification
Protein G purified from tissue culture supernatant
Modifications
Unmodified
Immunogen
Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-Terminus D1 domain of human LAG-3 (lymphocyte activation gene-3). Percent identity by BLAST analysis: Human (100%); Gorilla (93%); Gibbon (90%); Monkey (83%).
Epitope
aa70-99
Specificity
Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of human LAG-3.
Applications
  • IHC
  • IHC - Frozen
  • ICC
  • Western blot
  • Immunoprecipitation
  • Flow Cytometry (1:100)
  • Functional Assay
  • Applications tested for the base form of this product only
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Usage
The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested. Flow Cytometry - 1:100.
Presentation
PBS, 0.02% Sodium Azide
Storage
Store at 4°C. Do not freeze. Protect from light.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
About LAG3
P18627 NM_002286 P18627

Publications (0)

Customer Reviews (0)


Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 4/19/2024